ANZCTR search results

Study Synopsis Background: Post-Traumatic Stress Disorder (PTSD) is a mental illness that develops in some individuals following a traumatic event. PTSD can cause significant distress, poor function and detrimental health outcomes for patients as well as their primary relative/friend or carer and has been estimated to be prevalent in more than a third of both patients and relatives, though reported prevalence is highly variable. Objective: Quantify the burden of PTSD in survivors of out-of-hospital cardiac arrest (OHCA) and in their primary caregiver at 6 and 24-months and determine changes over time in PTSD rates. Method: This is a sub-study of the TTM2 Trial. All participants that have been included in the TTM2 trial who attend the 6-months follow-up for the main study are eligible for inclusion in the PTSD study. The primary carer of the participant is also eligible if they meet the following criteria: Witnessed the cardiac arrest OR visited the participant at least once in the ICU AND lives with the participant OR whom has weekly or more frequent contact (in person or over the telephone) with the participant AND attends the 6-months visit with the participant. The participant and their primary caregiver will be asked to complete a self-administered 20-item questionnaire (Post-traumatic stress CheckList-5 (PCL-5)). Outcome: Proportion of participants and primary caregivers meeting the mild, moderate, severe and extreme Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) categories for PTSD symptoms. Changes over time of PTSD rates at 6-months vs 24-months will also be reported.

This project evaluates the effectiveness of cognitive-behavioural therapy (CBT) for improving depressive symptoms for older adults living in residential aged care facilities. The therapy involves three components: Face to face CBT for residents, training and support for family or friends of residents (“family/friends”) and training and consultation with facility staff. Hence, the treatment involves a systemic approach involving residents, family/friends and facility staff. Using a cluster-randomised controlled trial, this project compares the effectiveness of the intervention over and above usual practice, for improving depressive symptoms in residents of aged care facilities.

The number of people needing a colonoscopy is going to increase in the future following the national rollout of the National Bowel Cancer Screening Program (NBCSP). The NBCSP was extended to include Australians 60 and 70 years in 2013 and 2015 respectively and biennial screening from 2017-18, meaning that the future demand for screening and surveillance endoscopy procedures is set to escalate, and the current service model will not meet demand. This has prompted reconsideration of current models of service delivery. It is important to gauge how well a novel service model will be received before the development of a role can occur. This study aims to hypothetically test a general service model that has not been wholly defined. The level of agreement or disagreement with the statements will indicate, in general terms, the level of support such a role would garner from the Department of Anaesthesia. Participants will have the opportunity to discuss their support or concerns for the program. Themes identified in these discussions will be used to influence future decision making. The survey and face to face interviews have been designed to be completed quickly and pose no risk of harm to the participants.

For shift workers there is an increased risk of 23% of developing obesity and 44% of developing type 2 diabetes. There are currently 1.5 million Australians (~16% of workforce population) who are at risk. The risk of obesity and type 2 diabetes in this population group do not appear to be related solely to overall energy intake. Previous research has shown that meal timing i.e. eating late into the night, as is common among shift worker, is associated with metabolic complications such as impaired glucose tolerance and insulin resistance, potentially contributing to weight gain. However, there is currently a lack of evidence to identify effective weight loss strategies in shift workers with obesity. We aim to compare three weight loss regimens in a population of shift workers to identify weight loss strategies that will a) result in successful weight loss and b) be flexible to the demanding lifestyles of the shift working population. This six month dietary intervention study will compare continuous energy restriction (diet 1) with intermittent fasting (5:2). The two fast days will either be days that participants work a day shift (diet 2) or days that participants work night shift (diet 3). The study hypothesises that each of the dietary interventions will be effective at inducing weight loss but there will be a differential effect of the diets across time on HOMA-IR (a measure of insulin resistance).

In patients in whom intubation of the airway is predicted to be difficult, a C-MAC D-blade videolaryngoscope™ (Karl Storz Endoscopy, Tuttlingen, Germany) is commonly used to improve visualisation of the Glottis. Due to the high angulation of the D-Blade it is not uncommon to encounter a "can see, cannot intubate" situation, This study will compare the intubation times of two airway adjuncts used with the CMAC D-blade - the Construct Medical Flexible Tip Bougie, and the GlideRite rigid stylet, We hypothesise that the flexible tip bougie will offer improved speed of intubation owing to its ability to adjust the direction of the bougie tip during the intubation.

The purpose of this study is to evaluate how a drug moves around the body. The drug is called C595 Mab and will be combined with some existing radioactive chemicals routinely used in cancer imaging, called 99mTc and 111In. Who is it for? You may be eligible for this study if you are aged 18 or older with locally advanced or metastasised pancreatic cancer. Study details All participants in this study will have their scheduled biopsy. After laboratory testing confirms eligibility, participants will receive an injection of C595 Mab with 99mTc through a needle in the arm. Participants will then have a one CT scan. Depending on the results, after two weeks new participants will have an injection of C595 Mab with 111In through a needle in the arm, and three CT scans. Participants that will receive either 99mTc or 111In injections will have their vital signs (like temperature, blood pressure, heart rate and pulse) monitored for a few hours after their injection. It is hoped this research will help provide further information on the safety and usefulness of C595 as part of a potential future therapy for pancreatic cancer.

This pilot randomised crossover study will seek to recruit volunteers with interstitial lung disease experiencing significant cough and dyspnoea. These volunteers will be administered nebulised furosemide in the context of exercise induced dyspnoea, with nebulised normal saline being used as a control. The response of the participants’ cough and dyspnoea to the administration of these agents will be recorded and compared. It is our hypothesis that the administration of nebulised furosemide will symptomatically improve the cough and dyspnoea experienced.

The purpose of this study is to investigate the efficacy and safety of Ivosidenib and Enasidenib in patients with acute myeloid Leukaemia or myelodysplastic syndrome (MDS). Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with AML or MDS with either an IDH1 or IDH2 mutation, with no previous chemotherapy treatment. Study details Participants in this study will receive the following treatments: 1.Up to two cycles of Induction: Cytarabine for 6 days and Daunorubicin once a day for 3 days through an infusion in the vein. You will be randomly assigned either a placebo (no treatment) or Enasidenib or Ivosidenaib orally with a tablet once a day for the whole cycle. 2.Up to three cycles of consolidation: Cytarabine twice a day through an infusion in the vein over 3 days. You may then receive either a placebo (no treatment) or Enasidenib or Ivosidenaib orally with a tablet once a day until the end of consolidation. 3.Maintenance treatment will be either a placebo (no treatment), Enasidenib or Ivosidenaib for up to two years. All participants will undertake blood tests, bone marrow biopsies, scans and questionnaires.

Registry of patients with biopsy-proven renal disorders enabled by a collaboration of the State Wide Clinical Renal Network , Renal Physicians from Hospital and Health Services across Pathology Queensland and CKD.QLD,The University of Queensland and governed by a steering committee. The principal aim of the Registry is to improve patient care and outcomes. The Registry will do this by profiling renal biopsy proven disorders in Queensland which will facilitate early recognition, benchmark management to best practice, and provide a platform to validate new care strategies. Specific objectives include: 1.Development of a prospective collection of clinical, laboratory, pathology, treatment and outcome data of patients with biopsy proven medical renal disease 2.Consolidation of data into a collated data set [Registry] 3.Evaluation of patient data to identify and facilitate improved clinical care and management 4.Support clinical research 5.Identification and development of health policies targeting patients with biopsy proven renal disorders 6.Develop links and collaborations with other registries nationally and internationally

Often research to improve the care of children after surgery involves following up patient recovery at home. Until now this has been done at Perth Children's Hospital by telephone interview, however telephone follow-up is time consuming and might be inconvenient for families. We will test an automated interactive SMS messaging system to communicate with families about their child’s pain at home after tonsillectomy with 100 families. We expect that this will be easier for researchers and more convenient for families, and that we will be able to contact more families successfully using this method.